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A B S T R A C T   
Migraine is a neurovascular disorder that is three times more prevalent in women than in men and represents a 
large socio-economic burden. Therefore, the development of new preventive medications is an urgent matter. 
Currently, calcitonin gene-related peptide (CGRP), a neuropeptide released from trigeminal fibres, is an 
important target for migraine treatment. Accordingly, antibodies directed against CGRP or its receptor, as well as 
small-molecule CGRP receptor antagonists, have been developed for the prophylactic and acute treatment of 
migraine. Results from clinical phase III trials show a significant decrease in migraine days and relatively mild 
side-effects. However, CGRP is not only present in the trigeminal nerve, but it is also abundant in perivascular 
nerve fibres. Moreover, CGRP levels and hormones vary between sexes and during different life stages, and 
hormones affect CGRP, with a seemingly greater role for CGRP in females. In this review we discuss whether 
these aspects could be associated with differences in response and efficacy of drugs interfering with the CGRP 
pathway. Furthermore, CGRP has been described as playing a protective role in ischemic events, and CGRP seems 
to play a larger role in cardiac ischemic events in female patients. As cardiovascular risk is increased in female 
migraine patients and also increases significantly in females after menopause, further research into the risk of 
blocking CGRP in these patients is needed.   
1. Introduction 
1.1. Migraine and CGRP 
Migraine is a highly prevalent, primary headache disorder. It is 
estimated that 15 % of the world population suffers from migraine, 
representing a large socioeconomic burden [1]. 
It is characterized by unilateral pulsating pain of moderate to severe 
intensity, often aggravated by physical activity and accompanied by 
nausea, vomiting, photophobia and phonophobia. When left untreated, 
typical attack duration is between 4 and 72 h [2]. A crucial role in the 
development of a migraine attack is attributed to the activation of the 
trigeminovascular system [3]. This system consists of sensory neurons of 
the trigeminal nucleus caudalis and the trigeminal ganglion, with the 
latter innervating cranial blood vessels. When activated, calcitonin 
gene-related peptide (CGRP) is released from the nerve endings sur-
rounding the meningeal blood vessels causing vasodilation, further 
activation of the trigeminal nerve and nociceptive transmission [4,5]. 
During a migraine attack levels of CGRP increase in jugular blood and 
normalize concomitantly with headache relief [3,6]. Moreover, infusion 
of CGRP in migraine patients induces a migraine-like headache [7]. 
1.2. Migraine treatment targeting CGRP 
While for the acute treatment of migraine medication is available 
that was specifically designed for migraine (i.e. triptans), for years 
prophylactic treatment consisted only of medication originally devel-
oped for diseases other than migraine, such as hypertension, epilepsy 
and depression. Due to their role in migraine pathophysiology, the tri-
geminovascular system and CGRP were identified as possible targets in 
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the treatment of migraine [3]. Simultaneously, classical (small mole-
cule) CGRP receptor antagonists and IgG type monoclonal antibodies 
targeting CGRP and the CGRP receptor were developed. Phase III trials 
with the antibodies as preventive treatment for migraine have shown a 
significant improvement in migraine with a favorable tolerability profile 
when compared to the current prophylactics. Unfortunately, even 
though they were specifically developed for the treatment of migraine, 
not all patients benefit from these antibodies [8]. 
1.3. CGRP and hormonal influences 
Migraine prevalence differs between men and women, with 75 % of 
patients being women. A strongly increased incidence is seen in women 
after menarche, with notable changes in occurrence during life and 
reproductive milestones [9]. 
Interestingly, ovarian hormone receptors have been described in all 
the components of the TVS and interactions between ovarian sex hor-
mones and CGRP levels have been described [9]. Moreover, the wide 
distribution of the CGRP receptors in vascular tissue points out a role for 
CGRP in regulation of the vascular tone. Indeed, CGRP has been 
described to participate in the homeostatic response to ischemic events 
[10]. In this review we will focus on the influence of hormones on 
migraine and its fluctuations throughout life, with especial focus on 
women, which may influence the response to CGRP-blocking medica-
tion and the possible risks which could accompany (long term) blockade 
of CGRP. 
2. Methods 
We performed an extensive search in PubMed. Our aim was to 
identify research papers that explored CGRP and migraine differences 
between sex and gender, as well as changes and potential risks through 
different life stages. Search terms used to identify literature included: 
migraine, menopause, pregnancy, cerebrovascular risk, cardiovascular 
risk, all separately combined with CGRP. Migraine was also combined 
with monoclonal antibodies. The results were filtered to show only 
English articles. Articles were then selected based on the abstracts. 
Additional articles were extracted from reference lists of original articles 
and review articles. 
3. Gender aspects 
3.1. Hormonal influences 
As mentioned above, the prevalence of migraine in women increases 
after menarche to a three-to-one ratio, when compared to men [11]. The 
symptoms men and women report differ as well, as female patients are 
more likely to report additional symptoms, including photophobia, 
phonophobia, nausea, vomiting and visual aura [11]. Moreover, for 
many female patients, migraine occurrence often correlates to specific 
phases of the menstrual cycle, the highest incidence being reported just 
before and during the first days of menstruation [12]. Conversely, dur-
ing pregnancy, patients experience less migraine attacks. During peri-
menopause, patients report an increase in migraine frequency with, 
eventually, a postmenopausal decrease [9,13]. 
An interaction between ovarian sex hormones and CGRP has also 
been suggested. In healthy subjects it has been shown that plasma CGRP 
levels in women are significantly higher than in men, with even higher 
plasma CGRP found in women using combined hormonal contraceptives 
[17]. Interestingly, Ibrahimi et al. investigated the trigeminal nerve-
mediated vasodilation during different phases of the menstrual cycle 
and showed cycle-dependent changes in healthy women, which were 
not observed in patients with menstrually-related migraine [14]. In the 
same study, estradiol levels during day 1–2 of the cycle were similar 
between healthy controls and patients with menstrually-related 
migraine, but in the luteal phase of the cycle (day 19–21), 
significantly lower estradiol levels were found in patients with 
menstrually-related migraine. Indeed, expression of sex hormone re-
ceptors has been reported in the components of the trigeminovascular 
system [2]. The decreased variability in estradiol levels throughout the 
menstrual cycle and the seemingly disturbed trigeminovascular cyclicity 
in the study of Ibrahimi et al. could correlate to the menstrually-related 
susceptibility to migraine of these patients, although the exact mecha-
nisms remain to be determined [14]. 
Approximately 25 % of migraine patients are men [11]. Therefore, a 
recent study analysed sex hormone levels in male patients and showed 
increased levels of estradiol in men with migraine when compared to 
healthy male controls [15], indicating that variations in ovarian steroid 
hormones could be associated with the migraine prevalence difference 
in both men and women. 
3.2. CGRP and pregnancy 
In pregnancy, important haemodynamic changes occur, such as in-
crease of the uteroplacental blood flow and decrease of the uterine 
vascular resistance [16]. An impairment of the uteroplacental circula-
tion is associated with intrauterine growth restriction and newborns 
small for gestational age [16,17]. CGRP has been described to be 
involved in the regulation of the fetoplacental vascular tone [18]. 
Indeed, in healthy pregnant women, CGRP levels are significantly 
increased throughout the pregnancy. In the postpartum phase, serum 
concentrations of CGRP decrease significantly to levels similar to 
nonpregnant women [19]. Moreover, in pregnant patients with 
pre-eclampsia and intrauterine growth restriction, CGRP levels are 
lower compared to normotensive pregnancies [20]. 
Certainly, migraine attacks are associated with increased levels of 
CGRP and an increase in CGRP is measured during pregnancy; however, 
migraine patients usually experience less migraine during pregnancy 
and puerperium [9]. This could be explained by a difference in local 
cranial CGRP levels that increase during migraine and systemic CGRP 
that plays a role in haemodynamic changes in pregnancy [9]. Alterna-
tively, high levels of CGRP in pregnancy could lead to a desensitization 
of the receptor, leading to a decrease in migraine. Moreover, considering 
that sex hormone receptors are present in the trigeminovascular system, 
the fluctuations in sex hormones during pregnancy could modulate the 
activation of the trigeminovascular system and/or the nociceptive 
transmission. 
3.3. CGRP and menopause 
It has been shown that there is a significant increase in CGRP during 
hot flushes [21]. Moreover, postmenopausal women who experience hot 
flushes have significantly higher levels of plasma CGRP and a higher 
total 24 h urine secretion of CGRP than premenopausal women and 
postmenopausal women who do not experience hot flushes [22,23]. As 
CGRP has a strong vasodilatory effect, increased levels of CGRP could be 
correlated to vasomotor symptoms and, thus, experiencing more hot 
flushes. 
Even though this clear relation between vasomotor symptoms and 
CGRP exists, the exact mechanism behind it is not completely under-
stood. Hot flushes are experienced as being very brief, in accordance 
with the short biological plasma half-life of CGRP [10]. In contrast, 
administration of exogenous human CGRP leads to local reddening for as 
long as 1− 6 h after administration [24,25]. 
A study in mice showed that blocking CGRP reduced flush-like 
symptoms [26], suggesting that anti-CGRP treatment, antagonists or 
antibodies, could potentially diminish perimenopausal vasomotor 
symptoms by stabilizing the CGRP fluctuations. Several studies on the 
effect of hormonal replacement therapy on CGRP levels have reported 
that after 3 months of treatment, the plasma concentration of CGRP in 
postmenopausal women significantly increases to levels similar to 
healthy fertile women [27,28], suggesting a reduced CGRP secretion 
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after menopause, probably associated to sex hormone deficiency [27]. 
Interestingly, while most migraine patients experience a decrease of 
migraine attacks during postmenopause, in patients with surgical 
ovariectomy, a worsening in migraine attacks has been described [29]. 
This disparity may be explained by the abrupt and marked decline in 
serum estradiol levels observed in ovariectomised patients, in contrast to 
the initial increase in estradiol secretion followed by a continuous but 
irregular decline observed in patients who have a physiological meno-
pause [30,31], but further studies should address the exact mechanisms 
behind. 
4. CGRP (receptor)-antibodies in migraine 
After discovering the role of CGRP in migraine, this peptide became a 
potential target for the development of new migraine treatments. Due to 
their long plasma half-life (about a month), the antibodies are only 
suitable for prophylactic treatment [32] and are administrated monthly 
or once every three months. This, combined with an excellent tolera-
bility in clinical trials [8], will lead to a higher compliance rate when 
compared to the current preventive migraine treatments. 
At the moment three antibodies against CGRP (fremanezumab, gal-
canezumab and eptinezumab), and one against the CGRP receptor 
(erenumab) have been developed. In recent years multiple phase III 
trials have been performed [8], which have all shown a statistically 
significant advantage compared to placebo. About 40–60 % of partici-
pants had at least 50 % reduction in migraine days. These numbers show 
that not all patients benefit from this treatment. The previously 
described differences in plasma levels of CGRP between men and 
women, the hormonal influences and the changes that occur in different 
life stages are yet to be studied as, perhaps, a partial explanation. 
Nonetheless, the development of these antibodies is of great value to the 
advancement in the treatment of migraine. 
5. Potential risks of blocking CGRP 
Due to their relatively large molecular weight, CGRP (receptor) an-
tibodies are not likely to pass the blood brain barrier and thus not likely 
to cause central side effects. Nonetheless, CGRP is located in both the 
peripheral and enteric nervous system. Although the most common 
adverse events reported are mild, such as local injection-site reactions 
(such as erythema and pain), and upper respiratory tract infections, all 
similar between the different antibodies, there have been a few cases of 
(fatal) cardiovascular events [33]. Furthermore, the long-term effects of 
blocking CGRP in humans are not well known [33,34]. Considering our 
knowledge of the presence and function of CGRP, a few potential risks 
that could accompany blocking CGRP will be discussed. 
5.1. Potential risks in pregnancy 
Because of its role in maternal haemodynamic adaptation and foetal 
growth, there is a theoretic risk for hypertension and foetal growth re-
striction when blocking CGRP during pregnancy. In pregnant rats, 
blocking CGRP with a CGRP receptor antagonist led to an increased 
systolic blood pressure, foetal growth retardation and an increased 
foetal mortality [35]. After inducing preeclampsia by administration of 
the nitric oxide (NO) synthase inhibitor L-NAME in pregnant rats 
through osmotic minipumps, a significant increase in foetal mortality 
was observed when compared to controls. The administration of CGRP 
in these rats caused a substantial reduction in blood pressure and in 
foetal mortality [36]. In contrast, a study in which they administrated 
erenumab during pregnancy, showed a similar rate of infant and foetal 
loss in the erenumab and the control group, even though they did find 
evidence of placental transfer [37]. The Foetal exposure to antibodies 
directed against CGRP or its receptor is likely to happen in the second 
half of pregnancy. IgG antibodies are known to be able to cross the 
placenta through the neonatal Fc receptor (FcRn) in syncytiotrophoblast 
cells, which become present after 20–22 weeks of pregnancy [38]. Thus, 
physicians should take into account this potential risk and consider the 
long half-life when prescribing these drugs. 
5.2. Potential cerebro- and cardiovascular risks 
Another potential concern of blocking CGRP is an increase of car-
diovascular risk. As migraine itself has been reported to be a risk factor 
for ischemic stroke and cardiovascular events, especially in women, and 
even more when using combined oral contraceptives, it is important to 
study whether anti migraine treatment does not increase this risk [10]. 
The exact underlying mechanism for this is still unknown, which makes 
it difficult to assess whether adding anti-CGRP treatment would 
augment this risk. 
Before menopausal age, the risk of cardiovascular events in women is 
much lower than in men. After menopause this risk increases up to 
similar rates as in men [10]. In postmenopausal women, higher serum 
total cholesterol, triglyceride and LDL levels than in premenopausal 
women have been described [22], which may be one of the underlying 
causes of the abrupt increase in cardiovascular events in post-
menopausal women. Additionally, Gupta et al. demonstrated that adi-
pose tissue of postmenopausal women has a significantly larger 
expression of β-CGRP compared to premenopausal women [39]. These 
changes in CGRP expression might be a physiological response to the 
change in lipid profile and act as a protective mechanism against car-
diovascular events. No safety concerns for cerebro- or cardiovascular 
events have been reported in the clinical trials with CGRP (receptor) 
antibodies, although there have been a few reported cases of cardio-
vascular events during treatment with these antibodies [40–42], that 
were assumed not to be treatment-related by the investigators. Note-
worthy, all trials excluded patients with a history of cardiovascular or 
cerebrovascular events. 
Even though the exact physiological function of CGRP has not been 
fully described, it is clear that after an ischemic event, CGRP is released, 
causing vasodilation [10], suggesting a protective role. Moreover, dur-
ing vascular inflammation, release of CGRP inhibits the proliferation of 
vascular smooth muscle cells, thus limiting the growth of atheromatous 
lesions [43]. This poses a concern as CGRP (receptor) blockade could 
lead to more extensive damage in an otherwise mild infarction. A small 
study performed in 2005 revealed no effect on cerebral blood flow or the 
diameter of the middle cerebral artery in the 3 h after infusion of a CGRP 
receptor antagonist. Additionally, no effect on the extracranial arteries 
or systemic haemodynamic was recorded [44]. While, indeed, in the 
acute phase of blocking CGRP there might be compensating physiolog-
ical mechanisms to maintain cerebral blood flow [10], it remains to be 
demonstrated whether similar mechanisms are effective on the long 
term. 
A recent study explored the cardiovascular safety of CGRP receptor 
blockade with erenumab, in a randomized, double-blind, placebo- 
controlled study in patients with stable angina. Patients received a single 
infusion of erenumab (140 mg) and subsequently performed an exercise 
treadmill test. No difference was found between the erenumab and 
placebo group regarding time to exercise-induced angina, systolic and 
diastolic blood pressure or heart rate [45]. This might indicate that 
antibodies directed against CGRP or its receptor are safe in patients with 
a history of cardiovascular events. However, the treadmill test took 
place 30 min after infusion of erenumab, while no evidence was pro-
vided to show whether the CGRP receptor was already blocked at the 
time of the treadmill test [46]. This could potentially have taken several 
hours, given the large molecular size of erenumab and the location of the 
CGRP receptor in the smooth muscle wall of the blood vessel. Further-
more, although the majority of migraine patients are women, the ma-
jority of patients in this trial were men with stable angina. It is important 
to have in mind that myocardial infarction in men is usually caused by 
occlusion of the proximal coronary circulation, while in women vaso-
spasm of the small intramyocardial parts of the coronary arteries, where 
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CGRP leads to much larger vasodilatory responses to CGRP [10], is more 
common (Fig. 1) [47]. This difference in pathophysiology could imply a 
different risk for men and women when blocking CGRP. Therefore, there 
is an urgency for safety studies with an adequate design, including the 
consideration of gender differences. 
6. Conclusion 
The first migraine-specific prophylactic treatment, e.g. CGRP (re-
ceptor)-antibodies, has been registered. Although CGRP has been 
marked as a specific target for migraine, not all migraine patients benefit 
from treatment. Plasma CGRP levels differ between men and women and 
change during pregnancy and around menopause. The differences be-
tween men and women could be associated with a difference in response 
and a difference in risks and side effects. Although clinical trials have 
shown only mild side effects, the presence of CGRP throughout the body 
and the lack of long term data is reason for concern. The potential risks 
discussed in this review need to be recognized and further investigated. 
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